VERICI DX PLC LS-001 risk profile
55 Elevated one input has moved against it
Measured 21 October 2026 from 63V's filed statements. Recomputed nightly.
55 (Elevated), driven by Cash conversion at 100, over 3 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | Reads pct_below_52w_high, volatility_1y_pct and avg_turnover_90d_usd. No reading is stored for this company. | |||
| Operating pressure | 43 | Elevated | Worsening | Costs outgrowing revenue — +2.9 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.02x |
| Leverage and coverage | 37 | Normal | Easing | Interest cover — -372.76x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for VERICI DX PLC LS-001